ArticleCancer cell2024
Integrated proteogenomic characterization of glioblastoma evolution.
Open access · greenAbstract readComment
In one paragraph
Article in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
34.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 79 citations in OpenAlex.
- Functional proteomic and phosphoproteomic profiling of routine FFPE CNS tumor tissue complements genomic and epigenomic characterization.Acta neuropathologica · 2026Article
- LRIG2 suppresses NK cell-induced GSDME-mediated pyroptosis via the LAMP1-STAT3 pathway in glioma.Journal for immunotherapy of cancer · 2026Article
- Glioblastoma recurrence: An NGS-centered seed-soil framework.Neoplasia (New York, N.Y.) · 2026Article
- Systems biology of Wnt signaling in glioma chemotherapy resistance: Integrating multi-omics mechanisms and emerging therapeutic vulnerabilities (Review).Oncology letters · 2026Review
- Enabling Variant Proteogenomic Assay Development Through a Peptide Target Selection Pipeline and Web Application.Proteomics · 2026Article
- The Invasive Margin of Glioblastoma as a Molecular Ecosystem: Spatial Heterogeneity, Tumor-Host Interactions, and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Exploring the landscape of targetable alterations in patients with glioblastoma.Nature reviews. Clinical oncology · 2026Review
- Development of K-CORE: a web-based platform for integrated clinico-genomic analysis.Life science alliance · 2026Article
- Patient-derived organoids predict personalized drug response and reveal alternative therapeutic options in glioblastoma.Cell reports. Medicine · 2026Article
- Spatial Omics Technologies in Glioblastoma Research: Principles, Applications, and Best Practices.Genes · 2026Review
- LFPM inhibition of RING1-mediated p53Cell death and differentiation · 2026Article
- Single-cell transcriptomics reveals MAFB-driven macrophage reprogramming and immune divergence in recurrent glioblastoma.BMC cancer · 2026Article
- Decoding glioblastoma evolution and heterogeneity through mechanistic modeling: implications for clinical translation.Journal of experimental & clinical cancer research : CR · 2026Review
- Role of NR2F2-mediated reprogramming of endothelial cells in glioblastoma progression.iScience · 2026Article
- Inferring translational efficiency from transcriptomes improves noncanonical neoantigen prioritization and cancer patient stratification.NPJ precision oncology · 2026Article
- T2Pdecoder enables protein-centric analyses from transcriptomic data.Nature communications · 2026Article
- Ligand-dependent corepressor suppresses angiogenesis and macrophage infiltration in gliobl astoma microenvironment via MCP-1 down-regulation.BMC biotechnology · 2026Article
- Copper transporters promote the malignant progression of glioblastoma by regulating the immunosuppressive tumour microenvironment via the SLC31A1-WNT5A axis.Journal of translational medicine · 2026Article
- Discovering proteo-transcriptomic networks via biologically informed heterogeneous graph learning.Nucleic acids research · 2026Article
- Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer.Genome biology · 2026Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
39 authors at 13 institutions in 7 countries.
Kyung-Hee KimDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea; Proteomics Core Facility, Research Core Center, Research Institute, National Cancer Center, Goyang, Korea.
Simona MigliozziSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Harim KooDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea; Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Jun-Hee HongDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Seung Min ParkDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Sooheon KimDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Hyung Joon KwonDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Seokjun HaDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Luciano GarofanoSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Young Taek OhSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Fulvio D'AngeloSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Chan Il KimDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Seongsoo KimDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Ji Yoon LeeDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Jiwon KimDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Jisoo HongDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Eun-Hae JangLaboratory of Neuroscience, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, Korea.
Bertrand MathonService de Neurochirurgie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France.
Anna-Luisa Di StefanoInstitut de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Equipe labellisée LNCC, Paris, France; Onconeurotek, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France; Department of Neurology, Foch Hospital, Suresnes, France.
Franck BielleInstitut de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Equipe labellisée LNCC, Paris, France; Onconeurotek, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France.
Alice LaurengeInstitut de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Equipe labellisée LNCC, Paris, France; Onconeurotek, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France.
Alexey I NesvizhskiiDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Eun-Mi HurLaboratory of Neuroscience, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, Korea; BK21 Four Future Veterinary Medicine Leading Education & Research Center, College of Veterinary Medicine, Seoul National University, Seoul, Korea.
Jinlong YinDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea; Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan, China.
Bingyang ShiHenan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan, China.
Youngwook KimDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Kyung-Sub MoonDepartment of Neurosurgery, Chonnam National University Hwasun Hospital and Medical School, Hwasun, Korea.
Jeong Taik KwonDepartment of Neurosurgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
Shin Heon LeeDepartment of Neurosurgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
Seung Hoon LeeDepartment of Neurosurgery, Eulji University School of Medicine, Daejeon, Korea.
Ho Shin GwakDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Anna LasorellaSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Biochemistry, University of Miami Miller School of Medicine, Miami, FL, USA.
Heon YooDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Marc SansonInstitut de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Equipe labellisée LNCC, Paris, France; Onconeurotek, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France. Electronic address: marc.sanson@aphp.fr.
Jason K SaDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea. Electronic address: jasonksa@korea.ac.kr.
Chul-Kee ParkDeparment of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea. Electronic address: nsckpark@snu.ac.kr.
Do-Hyun NamDepartment of Neurosurgery and Samsung Advanced Institute for Health Sciences and Technology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: nsnam@skku.edu.
Antonio IavaroneSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Neurological Surgery and Department of Biochemistry, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: axi435@med.miami.edu.
Jong Bae ParkDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea; Department of Clinical Research, Research Institute and Hospital, National Cancer Center, Goyang, Korea. Electronic address: jbp@ncc.re.kr.
National Cancer Center · KRUniversity of Miami · USKorea University · KRCentre National de la Recherche Scientifique · FRSeoul National University · KREulji University · KRHenan University · CNNational Cancer Center · USChonnam National University Hwasun Hospital · KRChung-Ang University Hospital · KRSamsung Medical Center · KRSorbonne Université · FRUniversity of Michigan · US
Funding
Oncogenic mechanisms, molecular stratification and therapeutic targets of brain tumorsR35CA253183 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Antonio Iavarone · 2021 to 2026
$5.2MEvolution and targeting of the functional states of glioblastomaR01CA268592 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Antonio Iavarone, ANNA LASORELLA · 2022 to 2026
$2.0MNCI NIH HHS R01 CA268592NCI NIH HHS R35 CA253183
Abstract
The evolutionary trajectory of glioblastoma (GBM) is a multifaceted biological process that extends beyond genetic alterations alone. Here, we perform an integrative proteogenomic analysis of 123 longitudinal glioblastoma pairs and identify a highly proliferative cellular state at diagnosis and replacement by activation of neuronal transition and synaptogenic pathways in recurrent tumors. Proteomic and phosphoproteomic analyses reveal that the molecular transition to neuronal state at recurrence is marked by post-translational activation of the wingless-related integration site (WNT)/ planar cell polarity (PCP) signaling pathway and BRAF protein kinase. Consistently, multi-omic analysis of patient-derived xenograft (PDX) models mirror similar patterns of evolutionary trajectory. Inhibition of B-raf proto-oncogene (BRAF) kinase impairs both neuronal transition and migration capability of recurrent tumor cells, phenotypic hallmarks of post-therapy progression. Combinatorial treatment of temozolomide (TMZ) with BRAF inhibitor, vemurafenib, significantly extends the survival of PDX models. This study provides comprehensive insights into the biological mechanisms of glioblastoma evolution and treatment resistance, highlighting promising therapeutic strategies for clinical intervention.
Indexed as
Brain NeoplasmsGlioblastomaProteogenomicsAnimalsCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmHumansNeoplasm Recurrence, LocalProteomicsProto-Oncogene Proteins B-rafXenograft Model Antitumor AssaysProto-Oncogene Proteins B-rafBRAFlongitudinal glioblastomaneuronalproteogenomicsrecurrencesynapse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.